PharmaTelevision - Takeda Strengthens its US Presence

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Takeda Strengthens its US Presence

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

Dr Greg Landes recently joined Takeda San Francisco as Vice President, Antibody Research where he is responsible for overseeing, and the management of, all research functions directed towards the discovery and advancement of antibody drugs. In this week's interview, he discusses the purpose of the company as it grows and its role in Takeda's globalisation plans. With a focus on his own department and the science that it performs, Dr Landes builds a picture of a company whose progress will be exciting to watch in the future.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The purpose of ResearchTakeda San Francisco.

Fintan Walton:

Hello welcome to Pharmaventures Business review here live in London. On this show I have Greg Landes who is Vice President of AntibodyResearch at Takeda San Francisco. Welcome to the show.

Greg Landes:

Fintanit's a pleasure to be here.

Fintan Walton:

Gregyou are just recently joined Takeda San Francisco. And Takeda San Francisco is clearly a subsidiary of Takeda in Japan what is the purpose of Takeda San Francisco?

Greg Landes:

Takeda San Francisco is a centre of excellence as you've already pointed out for Antibody discovery. It's recognized that antibodies are becoming an increasingly important type of drug molecule. There is only twenty two antibody drugs right now that are commercially available. We feel that in fact there is going to be quite a few more and Takeda has taken the initiative to go ahead and put in a world class structure in the birthplace of Biotech in the Bay area, go ahead and create antibody drugs.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Greg Landes

Vice President Antibody Research

Greg Landes is Vice President of Antibody Research for Takeda San Francisco (TSF). He joined the company in September 2008 with over 25 years of biopharmaceutical and biotechnology experience. Dr Landeshas held the position of Vice President at several companies including Lexicon Pharmaceuticals, Abgenix and Genzyme. At Lexicon, he managed bio therapeutics research activities related to the generation and characterization of target specific monoclonal antibodies, the use of monoclonal antibodies to determine the pharmacological tractability of the target in relevant disease models, and the conversion and re-engineering of mouse monoclonal antibodiesHe was a member of the joint steering committees for multiple drug discovery alliances and also served on Lexicon's scientific executive committee. At Abgenix, he was responsible for day-to-day operations for antibodygeneration and characterization while serving as a member of the joint steering teams with major alliance partners. Several antibody leads identified during his tenure at Abgenix have advanced to clinical development. At Genzyme, Dr. Landesrose to the level of VP of Genetics and Genomics and was responsible for target related activities in the area of human genetics and expression profiling. Dr. Landes has authored 49 scientific articles and is an inventor of 12 issued and several pending patents. He received his B.A. degree in chemistry and Ph.D. in biochemistry from the University of Kansas and was a post-doctoral fellow at UCLA where he received the Molecular Biology Institute Post-Doctoral Scholar Award followed by an NIH post-doctoral fellowship award.

Takeda San Francisco

Takeda San Francisco, Inc. ( TSF) was established in November 2007 as Takeda's global center for excellence for biologics. The company's main role is to support Takeda's therapeutic antibodyresearch through it's antibodytechnology platform. The platform is based on discovery, optimization and development technologies used to efficiently generate Investigational New Drug (IND) candidates for the treatment of cancer, inflammatory and metabolic diseases. Takeda was founded in 1781 and is located in Osaka, Japan. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine through research and by developing pharmaceutical products. In 2007 the company recorded over $14B in sales. Takeda markets a number of blockbuster drugs discovered through its internal research programs including Actos (diabetes), Blopress (cardiovascular disease), and Prevacid (ulcer). Takeda has more than 4000 US-based employees and is rapidly growing its US operation.